Skip to main content

Table 3 Comparison of baseline characteristics of hypertensive adults according to antihypertensive treatment

From: Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19

Characteristic Antihypertensive treatment
(n = 1,044)
ACEI/ARB
(n = 782)
Non-ACEI/ARB
(n = 262)
P-value
Age (yr) 63.8 ± 14.1 63.0 ± 14.2 66.2 ± 13.6 0.002
Male sex 525 (50.3) 401 (51.3) 124 (47.3) 0.268
Comorbidity     
Diabetes 410 (39.3) 333 (42.6) 77 (29.4) 0.002
Dyslipidemia 620 (59.4) 481 (61.5) 139 (53.1) 0.016
Chronic kidney disease 177 (17.0) 144 (18.4) 33 (12.6) 0.030
Chronic obstructive pulmonary disease 181 (17.3) 134 (17.1) 47 (17.9) 0.766
Cancer 119 (11.4) 80 (10.2) 39 (14.9) 0.040
Cardiovascular disease 358 (34.3) 261 (33.4) 97 (37.0) 0.282
Ischemic heart disease 185 (17.7) 137 (17.5) 48 (18.3) 0.769
Myocardial infarction 27 (2.6) 23 (2.9) 4 (1.5) 0.212
Stroke 137 (13.1) 97 (12.4) 40 (15.3) 0.235
Congestive heart failure 163 (15.6) 113 (14.5) 50 (19.1) 0.074
Antihypertensive treatment     
ACEI 51 (4.9) 51 (6.5) 0 < 0.001
ARB 744 (71.3) 744 (95.1) 0 < 0.001
β-blockers 183 (17.5) 122 (15.6) 61 (23.3) 0.005
Calcium channel blockers 593 (56.8) 422 (54.0) 171 (65.3) 0.001
Diuretics 223 (21.4) 187 (23.9) 36 (13.7) 0.001
Others 100 (9.6) 48 (6.1) 52 (19.8) < 0.001
  1. Data are presented as mean ± standard deviation or number (%)
  2. ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers